4,906 Shares of Incyte Corporation $INCY Acquired by Wedbush Securities Inc.

Wedbush Securities Inc. purchased a new stake in shares of Incyte Corporation (NASDAQ:INCY) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 4,906 shares of the biopharmaceutical company’s stock, valued at approximately $595,000.

Several other institutional investors also recently bought and sold shares of the stock. Fifth Third Wealth Advisors LLC increased its holdings in shares of Incyte by 97.3% during the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 37,373 shares of the biopharmaceutical company’s stock valued at $4,535,000 after purchasing an additional 18,430 shares in the last quarter. Inspire Investing LLC lifted its stake in shares of Incyte by 14.7% in the 3rd quarter. Inspire Investing LLC now owns 38,721 shares of the biopharmaceutical company’s stock valued at $4,699,000 after purchasing an additional 4,972 shares during the period. Root Financial Partners LLC acquired a new position in shares of Incyte in the 3rd quarter valued at $103,000. Marion Wealth Management purchased a new stake in Incyte during the third quarter worth $268,000. Finally, Crossmark Global Holdings Inc. boosted its holdings in Incyte by 28.0% during the third quarter. Crossmark Global Holdings Inc. now owns 114,122 shares of the biopharmaceutical company’s stock worth $13,849,000 after buying an additional 24,983 shares in the last quarter. 96.97% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Incyte

In related news, EVP Patrick Mayes sold 41,899 shares of the firm’s stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $119.46, for a total value of $5,005,254.54. Following the transaction, the executive vice president directly owned 61,441 shares of the company’s stock, valued at approximately $7,339,741.86. This trade represents a 40.54% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Pablo Cagnoni sold 2,642 shares of Incyte stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $112.71, for a total value of $297,779.82. Following the completion of the sale, the insider owned 183,200 shares in the company, valued at approximately $20,648,472. The trade was a 1.42% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 55,342 shares of company stock valued at $6,659,208 in the last three months. Corporate insiders own 16.20% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. UBS Group reaffirmed a “neutral” rating and issued a $127.00 price objective on shares of Incyte in a report on Monday, October 5th. Sanford C. Bernstein reissued a “market perform” rating and set a $104.00 target price on shares of Incyte in a research note on Thursday, August 13th. Royal Bank Of Canada raised their target price on Incyte from $109.00 to $114.00 and gave the company a “sector perform” rating in a research report on Thursday, October 8th. Mizuho lifted their price target on Incyte from $121.00 to $137.00 and gave the company an “outperform” rating in a research note on Tuesday, August 4th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Incyte in a report on Tuesday. Twelve investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Incyte has an average rating of “Hold” and an average target price of $131.43.

Incyte News Roundup

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: New ESMO 2026 data for INCB161734 and INCA33890 advanced Incyte’s gastrointestinal-cancer portfolio. INCB161734 reportedly produced lasting tumor responses in pancreatic cancer, positioning Incyte as a credible competitor in the KRAS G12D treatment race. EMSO 2026: Incyte a firm contender in G12D pancreatic cancer race as early candidate shines
• Positive Sentiment: Incyte said it is “neck and neck” with Revolution Medicines in the KRAS G12D pancreatic-cancer market, suggesting meaningful commercial potential if its candidate continues to demonstrate durable efficacy. ESMO: Why Incyte sees itself neck and neck with RevMed in KRAS G12D pancreatic cancer race
• Positive Sentiment: H.C. Wainwright reiterated its Buy rating and $152 price target, citing the pancreatic-cancer data as evidence that Incyte may be undervalued. Incyte KRAS G12D PDAC data underscore undervalued opportunity
• Positive Sentiment: Incyte and Genmab agreed to evaluate a three-drug combination for first-line KRAS G12D-mutated metastatic colorectal cancer, expanding the potential reach of the companies’ targeted-oncology collaboration. Incyte and Genmab collaborate to develop a new colorectal cancer therapy
• Neutral Sentiment: Morgan Stanley maintained a Hold rating. The firm sees promise in Incyte’s oncology pipeline but believes long-term development execution and program timing risks temper the near-term investment case. Balanced view on Incyte

Incyte Price Performance

Shares of NASDAQ INCY opened at $116.60 on Wednesday. The firm has a fifty day moving average of $120.99 and a 200 day moving average of $107.96. Incyte Corporation has a one year low of $84.02 and a one year high of $132.60.

Incyte (NASDAQ:INCY) last posted its quarterly earnings data on Tuesday, July 28th. The biopharmaceutical company reported $3.09 earnings per share for the quarter, topping analysts’ consensus estimates of $2.15 by $0.94. The company had revenue of $1.67 billion for the quarter, compared to analyst estimates of $1.50 billion. The business’s revenue was up 37.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.57 earnings per share. As a group, equities research analysts forecast that Incyte Corporation will post 1.97 earnings per share for the current fiscal year.

Incyte Profile

Incyte Corporation is a biopharmaceutical company that discovers, develops and commercializes medicines for oncology and inflammatory or autoimmune diseases. The company focuses on therapies that target specific biological pathways, including Janus kinase (JAK), fibroblast growth factor receptor (FGFR) and other mechanisms involved in cancer and immune-related conditions.

Its key products include Jakafi (ruxolitinib), a JAK inhibitor used in the United States for certain blood cancers and graft-versus-host disease; Opzelura (ruxolitinib cream), a topical treatment for atopic dermatitis and nonsegmental vitiligo; and Pemazyre (pemigatinib), an FGFR inhibitor approved for selected patients with cholangiocarcinoma and certain myeloid or lymphoid neoplasms.